Every 424B that Abivax SA (ABVX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ABVX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABVX filings page.
Abivax SA is conducting a public offering of 6,400,000 ADSs at $125.00 per ADS. The offering price implies gross proceeds of $800,000,000 before underwriting discounts; proceeds to the company before expenses are $762,000,000. The underwriters have a 30-day option to purchase up to 960,000 additional ADSs.
The company recently repurchased royalty certificates for aggregate consideration of $90.0 million, funded half in cash and half by issuing 403,347 ordinary shares (including ADSs). Abivax reported positive topline Phase 3 maintenance results for obefazimod in ulcerative colitis, with higher response and remission rates at the 50 mg dose in exploratory cohorts and safety findings summarized across treatment arms.
Abivax SA is offering up to $600,000,000 of American Depositary Shares (ADSs), each representing one ordinary share. The ADSs trade on Nasdaq under the symbol ABVX and the ordinary shares trade on Euronext Paris under ABVX. The prospectus supplement describes offering mechanics, underwriting arrangements and customary lock-ups, and registers resale of ADSs issued in a prior private placement in connection with a $90.0 million royalty certificate repurchase (403,347 ADSs issued).
The supplement also discloses positive topline results from Part 2 of the Phase 3 ABTECT 44‑week maintenance trial for obefazimod, including Week 44 clinical remission of 37.2% for the 50 mg arm (induction non-responders) and safety tables summarizing treatment-emergent adverse events and malignancy incidence metrics used for exposure‑adjusted comparisons.
Abivax SA is registering the offer and resale of up to 403,347 ADSs, each representing one ordinary share, for sale by the selling shareholders under a prospectus supplement. The ADSs were issued as part of a repurchase of royalty certificates for an aggregate consideration of $90.0 million, consisting of $45.0 million paid in cash and $45.0 million paid by issuance of 403,347 ordinary shares/ADSs. The company states it will not receive any proceeds from resale by the selling shareholders and has paid or will pay registration fees; selling shareholders will bear selling commissions and similar expenses. The registration reflects the selling shareholders’ registration rights under a Purchase Agreement and permits resale by those holders or their permitted transferees in various transaction types described in the Plan of Distribution.